Callan Family Office LLC Makes New Investment in Waters Co. (NYSE:WAT)

Callan Family Office LLC bought a new position in shares of Waters Co. (NYSE:WAT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 821 shares of the medical instruments supplier’s stock, valued at approximately $305,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kennebec Savings Bank acquired a new position in Waters during the third quarter worth about $33,000. Bank of Jackson Hole Trust purchased a new stake in shares of Waters in the fourth quarter valued at about $34,000. Ashton Thomas Securities LLC purchased a new stake in shares of Waters in the third quarter valued at about $35,000. Fortitude Family Office LLC lifted its holdings in shares of Waters by 235.7% in the fourth quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 66 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Waters by 129.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 53 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

WAT has been the topic of several recent research reports. Sanford C. Bernstein raised shares of Waters from a “market perform” rating to an “outperform” rating and set a $430.00 price target on the stock in a report on Friday, January 10th. Barclays raised shares of Waters from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $360.00 to $415.00 in a research note on Monday, February 10th. StockNews.com downgraded shares of Waters from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Scotiabank raised shares of Waters from a “sector perform” rating to a “sector outperform” rating and upped their price objective for the company from $430.00 to $450.00 in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Waters from $380.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, March 6th. Eleven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $391.07.

Waters Stock Performance

NYSE:WAT opened at $390.52 on Tuesday. Waters Co. has a fifty-two week low of $279.24 and a fifty-two week high of $423.56. The firm’s 50 day moving average is $391.02 and its two-hundred day moving average is $369.52. The company has a market cap of $23.20 billion, a P/E ratio of 36.46, a P/E/G ratio of 3.79 and a beta of 1.00. The company has a quick ratio of 0.65, a current ratio of 0.94 and a debt-to-equity ratio of 1.14.

Waters (NYSE:WAT) last released its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. Analysts expect that Waters Co. will post 12.86 EPS for the current year.

Waters Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.